News
Duchenne Muscular Dystrophy, gene therapy
Digest more
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...
A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...
Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory ...
The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback